We are monitoring the impact of COVID-19 & Recession alarm on Latin America Multiple Myeloma Therapeutics Market Get in touch with us for detailed analysis Know More
Share on

Latin America Multiple Myeloma Therapeutics Market Research Report - Segmented By Treatment Type, Drug Type & Country (Mexico, Brazil, Argentina, Chile & Rest of Latin America) - Industry Analysis, Size, Share, Growth, Trends & Forecasts (2022 to 2027)

Published: January, 2022
ID: 803
Pages: 137

Latin America Multiple Myeloma Therapeutics Market Size (2022 to 2027)

The multiple myeloma therapeutics market in Latin America was worth USD 1.08 billion in 2022 and is estimated to be growing at a CAGR of 5.33% and worth USD 1.41 billion by 2027.

The Latin American multiple myeloma therapeutics market is projected to be primarily driven by the increasing aging population, rising prevalence for multiple myeloma, increasing obese population, rising healthcare expenditures, and increased focus on customized drugs. The worldwide incidence of multiple myeloma is currently at approximately 160,000, and the mortality is around 106,000. Likewise, the age-standardized incidence of multiple myeloma ranges between 0.54 and 5.3 per 100,000. Furthermore, the various benefits of therapeutic drugs have increased with consumer awareness of the disease, which, coupled with the growing rate of tests that help with early detection of the disease, is anticipated to drive the market's growth rate.

Additionally, increased efforts by various governments and public health organizations to support new treatment options for the patients positively impact the market. Continuous advancements in newer emerging therapies like monoclonal antibodies show promising results in treating patients with multiple myeloma and drive market growth. In recent years, several drugs have been explored to reduce the number of side effects seen in the patient during and after the post-recovery stage of using these anti-cancer drugs.

Unmet market demand and growing supply chain strategies for multiple myeloma therapeutics drugs will provide new growth opportunities for the market to grow during the upcoming years.

On the other hand, the limited target population of patients, the high price of therapeutic drugs and procedures, and the increased chances of end-stage complications are key factors that will harm the Latin America multiple myeloma therapeutics market during the forecast period. In addition, the long-term burden of taking anti-cancer drugs will result in many complications due to the narrow range of action in certain patients with pre-existing mortalities. The lack of knowledge about new and innovative cancer therapeutics in low economy countries with inadequate healthcare infrastructure poses a challenge to the market.

This research report on the Latin America multiple myeloma therapeutics market has been segmented and sub-segmented into the following categories

By Treatment Type:

  • Chemotherapy      
    • Anthracycline antibiotic
    • Alkylating agent
  • Targeted Therapy
    • Proteasome inhibitor

By Drug Type:

  • Corticosteroids     
    • Dexamethasone (Decadron)
    • Prednisone (Deltasone/Orasone)
  • Immunomodulatory agents             
    • Thalidomide (Thalomid)
    • Lenalidomide (Revlimid)
    • Arsenic trioxide (Trisenox)
    • Plerixafor (Mozobil)

By Country:

  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Rest of Latin America

In 2022, the regional market in Brazil dominated the Latin America multiple myeloma therapeutics market and is projected to continue with this trend over the forecast period. Various factors such as high demand for disease-specific treatments, increased adoption of new technologies, improving health care infrastructure, a higher level of patient awareness, and a high prevalence of multiple myeloma will drive the market in this region. In the Latin American region, the estimated number is 1.71 for incidence and 1.31/100,000 for mortality for multiple myeloma.

Mexico is considered the second growing regional market due to key players in this region, the significant increase in medical tourism, and the increase in population growth. In an important study conducted in 2015, 2569 patients with MM were reviewed, out of which 2039 unique patients were hospitalized and approximately 1169 deaths. The incidence rate for multiple myeloma was recorded at 1.16/100,000 inhabitants-year during the study period.

Other Latin American regions such as Peru, Argentina, Ecuador, and Columbia will grow due to the increase in generic manufacturers, rise in disposable income, and increasing healthcare infrastructure.

KEY MARKET PLAYERS:

Companies playing a significant role in the Latin America multiple myeloma therapeutics market profiled in this report are AB Science SA, AbbVie Inc., Ablynx NV, Acceleron Pharma Inc., IGF Oncology LLC., ImmunGene Inc., Millennium Pharmaceuticals Inc., MimiVax LLC, Mirna Therapeutics, RedHill Biopharma Ltd., Rhizen Pharmaceuticals S.A., Terpenoid Therapeutics Inc., Teva Pharmaceutical Industries Ltd., TG Therapeutics Inc., and Johnson and Johnson.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 New Developments               

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 By Treatment Type                 

                                5.1.1 Chemotherapy      

                                                5.1.1.1 Anthracycline antibiotic

                                                5.1.1.2 Alkylating agent

                                5.1.2 Targeted Therapy

                                                5.1.2.1 Proteasome inhibitor

                5.2 By Drug Type

                                5.2.1 Corticosteroids      

                                                5.2.1.1 Dexamethasone (Decadron)

                                                5.2.1.2 Prednisone (Deltasone/Orasone)

                                5.2.2 Immunomodulatory agents             

                                                5.2.2.1 Thalidomide (Thalomid)

                                                5.2.2.2 Lenalidomide  (Revlimid)

                                                5.2.2.3 Arsenic trioxide  (Trisenox)

                                                5.2.2.4 Plerixafor  (Mozobil)

6. Geographical Analysis                                              

                6.1 Introduction                               

                6.2 Brazil                             

                6.3 Mexico                         

                6.4 Argentina                    

                6.5 Rest of Latin America                             

7. Pipeline Product Analysis                                        

                7.1 Overview                                    

                7.2 Pipeline Development Landscape                                    

                7.3 Molecular Targets in the Pipeline                                      

                7.4 Clinical Trials (by Stage of Development, Indication, Molecule Type and Molecular Target)

                                7.4.1 Failure Rate            

                                7.4.2 Clinical Trial Duration           

                                7.4.3 Clinical Trial Size    

8. Strategic Analysis                                       

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental       

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services              

                                8.2.5 Competitive Rivalry within the Industry     

9. Market Leaders' Analysis                                        

                9.1 AB Science SA                            

                                9.1.1 Overview 

                                9.1.2 Product Analysis   

                                9.1.3 Strategic Evaluation and Operations            

                                9.1.4 Financial analysis  

                                9.1.5 Legal issues             

                                9.1.6 Recent Developments       

                                9.1.7 SWOT analysis       

                                9.1.8 Analyst View          

                9.2 AbbVie Inc.                 

                9.3 Ablynx NV                   

                9.4 Acceleron Pharma Inc.                           

                9.5 IGF Oncology LLC.                    

                9.6 ImmunGene Inc.                      

                9.7 Millennium Pharmaceuticals Inc.                       

                9.8 MimiVax LLC                              

                9.9 Mirna Therapeutics                 

                9.10 RedHill Biopharma Ltd.                        

                9.11 Rhizen Pharmaceuticals S.A.                             

                9.12 Terpenoid Therapeutics Inc.                             

10. Competitive Landscape                                         

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                      

                10.4 New Product Launches                       

11. Expert Opinions                                        

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 New Developments               

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 By Treatment Type                 

                                5.1.1 Chemotherapy      

                                                5.1.1.1 Anthracycline antibiotic

                                                5.1.1.2 Alkylating agent

                                5.1.2 Targeted Therapy

                                                5.1.2.1 Proteasome inhibitor

                5.2 By Drug Type

                                5.2.1 Corticosteroids      

                                                5.2.1.1 Dexamethasone (Decadron)

                                                5.2.1.2 Prednisone (Deltasone/Orasone)

                                5.2.2 Immunomodulatory agents             

                                                5.2.2.1 Thalidomide (Thalomid)

                                                5.2.2.2 Lenalidomide  (Revlimid)

                                                5.2.2.3 Arsenic trioxide  (Trisenox)

                                                5.2.2.4 Plerixafor  (Mozobil)

6. Geographical Analysis                                              

                6.1 Introduction                               

                6.2 Brazil                             

                6.3 Mexico                         

                6.4 Argentina                    

                6.5 Rest of Latin America                             

7. Pipeline Product Analysis                                        

                7.1 Overview                                    

                7.2 Pipeline Development Landscape                                    

                7.3 Molecular Targets in the Pipeline                                      

                7.4 Clinical Trials (by Stage of Development, Indication, Molecule Type and Molecular Target)

                                7.4.1 Failure Rate            

                                7.4.2 Clinical Trial Duration           

                                7.4.3 Clinical Trial Size    

8. Strategic Analysis                                       

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental       

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services              

                                8.2.5 Competitive Rivalry within the Industry     

9. Market Leaders' Analysis                                        

                9.1 AB Science SA                            

                                9.1.1 Overview 

                                9.1.2 Product Analysis   

                                9.1.3 Strategic Evaluation and Operations            

                                9.1.4 Financial analysis  

                                9.1.5 Legal issues             

                                9.1.6 Recent Developments       

                                9.1.7 SWOT analysis       

                                9.1.8 Analyst View          

                9.2 AbbVie Inc.                 

                9.3 Ablynx NV                   

                9.4 Acceleron Pharma Inc.                           

                9.5 IGF Oncology LLC.                    

                9.6 ImmunGene Inc.                      

                9.7 Millennium Pharmaceuticals Inc.                       

                9.8 MimiVax LLC                              

                9.9 Mirna Therapeutics                 

                9.10 RedHill Biopharma Ltd.                        

                9.11 Rhizen Pharmaceuticals S.A.                             

                9.12 Terpenoid Therapeutics Inc.                             

10. Competitive Landscape                                         

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures    

                10.4 New Product Launches                       

11. Expert Opinions                                        

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                               

  1. Latin America Multiple Myeloma Therapeutics Market By Region, From 2022 - 2027 (USD Billion)
  2. Latin America Multiple Myeloma Therapeutics Market By Treatment Type, From 2022 - 2027 (USD Billion)
  3. Latin America Chemotherapy Market By Region, From 2022 - 2027 (USD Billion)
  4. Latin America Targeted Therapy Market By Region, From 2022 - 2027 (USD Billion)
  5. Latin America Multiple Myeloma Therapeutics Market By Drug Type, From 2022 - 2027 (USD Billion)
  6. Latin America Corticosteroids Market By Region, From 2022 - 2027 (USD Billion)
  7. Latin America Immunomodulatory agents Market By Region, From 2022 - 2027 (USD Billion)
  8. Brazil Multiple Myeloma Therapeutics Market By Treatment Type, From 2022 - 2027 (USD Billion)
  9. Brazil Multiple Myeloma Therapeutics Market By Drug Type, From 2022 - 2027 (USD Billion)
  10. Argentina Multiple Myeloma Therapeutics Market By Treatment Type, From 2022 - 2027 (USD Billion)
  11. Argentina Multiple Myeloma Therapeutics Market By Drug Type, From 2022 - 2027 (USD Billion)
  12. Mexico Multiple Myeloma Therapeutics Market By Treatment Type, From 2022 - 2027 (USD Billion)
  13. Mexico Multiple Myeloma Therapeutics Market By Drug Type, From 2022 - 2027 (USD Billion)
  14. Latin America Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  15. Latin America Anthracycline Antibiotic Market By Region, From 2022 - 2027 (USD Billion)
  16. Latin America Alkylating Agent Market By Region, From 2022 - 2027 (USD Billion)
  17. Brazil Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  18. Argentina Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  19. Mexico Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  20. Latin America Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  21. Latin America Melphalan (Alkeran) Market By Region, From 2022 - 2027 (USD Billion)
  22. Latin America Liposomal doxorubicin (Doxil) Market By Region, From 2022 - 2027 (USD Billion)
  23. Brazil Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  24. Argentina Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  25. Mexico Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  26. Latin America Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  27. Latin America Doxorubicin (Adriamycin) Market By Region, From 2022 - 2027 (USD Billion)
  28. Latin America Cyclophosphamide (Neosar) Market By Region, From 2022 - 2027 (USD Billion)
  29. Latin America Vincristine (Oncovin) Market By Region, From 2022 - 2027 (USD Billion)
  30. Latin America Carmustine (BiCNU) Market By Region, From 2022 - 2027 (USD Billion)
  31. Brazil Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  32. Argentina Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  33. Mexico Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  34. Latin America Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2022 - 2027 (USD Billion)
  35. Latin America Bortezomib (Velcade) Market By Region, From 2022 - 2027 (USD Billion)
  36. Latin America Carfilzomib (Kyprolis) Market By Region, From 2022 - 2027 (USD Billion)
  37. Brazil Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2022 - 2027 (USD Billion)
  38. Argentina Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2022 - 2027 (USD Billion)
  39. Mexico Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2022 - 2027 (USD Billion)
  40. Latin America Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2022 - 2027 (USD Billion)
  41. Latin America Dexamethasone (Decadron) Market By Region, From 2022 - 2027 (USD Billion)
  42. Latin America Prednisone (Deltasone/Orasone) Market By Region, From 2022 - 2027 (USD Billion)
  43. Brazil Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2022 - 2027 (USD Billion)
  44. Argentina Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2022 - 2027 (USD Billion)
  45. Mexico Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2022 - 2027 (USD Billion)
  46. Latin America Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2022 - 2027 (USD Billion)
  47. Latin America Thalidomide (Thalomid) Market By Region, From 2022 - 2027 (USD Billion)
  48. Latin America Lenalidomide (Revlimid) Market By Region, From 2022 - 2027 (USD Billion)
  49. Latin America Arsenic trioxide (Trisenox) Market By Region, From 2022 - 2027 (USD Billion)
  50. Latin America Plerixafor (Mozobil) Market By Region, From 2022 - 2027 (USD Billion)
  51. Brazil Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2022 - 2027 (USD Billion)
  52. Argentina Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2022 - 2027 (USD Billion)
  53. Mexico Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

2875


pdf excel
$

3220


pdf excel powerbi
$

4600


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2875

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample